SLC22A4 and chronic myelogenous leukemia, BCR-ABL1 positive: Studies evaluating the possible correlation between clinical endpoints and polymorphisms of SLC22A1, OCTN1, OATP1A2 and CYP3A5 genes, their mRNA levels or transporter activity in CML patients treated with imatinib.